Vor Biopharma director granted 57,162 options
Vor Biopharma Inc. reported that director Andrew David Levin was granted a stock option covering 57,162 shares of common stock at an exercise price of $14.09 per share.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Vor Biopharma Inc. reported that director Andrew David Levin was granted a stock option covering 57,162 shares of common stock at an exercise price of $14.09 per share. The option expires on June 10, 2036 and is a compensation-related award.
One thirty-sixth of the option vests and becomes exercisable each month starting on July 11, 2026, subject to his continued service. Under an arrangement with RA Capital Management, L.P., Levin holds this option for the benefit of the RA Capital Healthcare Fund, L.P. and is obligated to turn over any net cash or stock received, and he therefore disclaims beneficial ownership of the option and underlying shares.
Insider Trade Summary
Grant/Award: 57,162 shares
Grant/Award
1 txn
Insider
Levin Andrew David
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock option (right to buy) | 57,162 | $0.00 | $0.00 |
Holdings After Transaction:
Stock option (right to buy) — 57,162 contracts (Direct)
Footnotes (2)
- F1. One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter, subject to the Reporting Person's continued service through each such vesting date.
- F2. Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Key Figures
Option grant size: 57,162 shares
Exercise price: $14.09 per share
Expiration date: June 10, 2036
+2 more
5 metrics
Option grant size
57,162 shares
Stock option covering Vor Biopharma common stock
Exercise price
$14.09 per share
Strike price of granted stock option
Expiration date
June 10, 2036
Option term end date
Vesting schedule
1/36 monthly
One thirty-sixth vests monthly starting July 11, 2026
Shares after transaction
57,162 derivative shares
Total option shares following grant
Key Terms
stock option, vest, beneficial ownership, advisory fees, +1 more
5 terms
stock option financial
"The Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P."
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"One thirty-sixth of the shares subject to the option shall vest and become exercisable on July 11, 2026 and each month thereafter"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
beneficial ownership financial
"The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock."
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
advisory fees financial
"net cash or stock received from the option, which will offset advisory fees owed by the Fund to the Adviser."
Advisory fees are payments made to financial advisors or investment managers for guidance, portfolio management, or other services, typically charged as a fixed amount or a percentage of assets under management. They matter because they lower an investor’s net returns—like paying a mechanic to tune a car, you expect better performance, so investors weigh whether the cost is justified by higher returns, better risk control, or convenience.
grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Vor Biopharma (VOR) report for Andrew Levin?
Vor Biopharma reported a grant of stock options to director Andrew Levin for 57,162 shares at an exercise price of $14.09 per share. The award is a compensation-related acquisition rather than an open-market purchase or sale of common stock.
How do the 57,162 Vor Biopharma (VOR) options granted to Andrew Levin vest?
The 57,162 stock options vest in equal monthly installments, with one thirty-sixth vesting starting on July 11, 2026. Vesting then continues each month thereafter, and each vesting date is conditioned on Levin’s continued service through that date.
What is the exercise price and expiration date of the Vor Biopharma (VOR) options?
The options granted to Andrew Levin have an exercise price of $14.09 per share and expire on June 10, 2036. This defines the price at which the underlying Vor Biopharma common shares can be purchased before expiration, once vested.
Who ultimately benefits from Andrew Levin’s Vor Biopharma (VOR) stock option grant?
According to the filing, Levin holds the option for the benefit of the RA Capital Healthcare Fund, L.P.. Under an arrangement with RA Capital Management, any net cash or stock received offsets advisory fees, and Levin disclaims beneficial ownership.
Does the Vor Biopharma (VOR) Form 4 show an open-market buy or sell by Andrew Levin?
No, the Form 4 reports a grant of stock options as compensation, coded as an acquisition (A), not an open-market purchase or sale. It is a derivative award tied to Vor Biopharma common stock rather than a direct stock trade.
AI-generated analysis. How Rhea-AI works. Not financial advice.
